Other recent partnerships in the molecular glue degrader category include Takeda's recent $1 billion-plus link-up with Degron Therapeutics, a $1.46 billion deal between Novo Nordisk and Neomorph ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback